RNA INTERFERENCE AND RETIGABINE THERAPY PROTECT AGAINST HEREDITARY HEARING LOSS
Grant number: 546493 | Funding period: 2011 - 2014
The preservation of hearing function is central to the treatment of individuals who are genetically predisposed to hearing loss. At present only synthetic hearing aids and cochlear implants can provide functional improvement, albeit sub-optimal. The studies described here will seek to prevent hearing loss by reducing the damaging effects of defective genes. Gene therapies that reduce the effect of these defective genes and a drug that enhances the activity of functional genes will be developed.
Related publications (6)
Advancing genetic testing for deafness with genomic technology
A Eliot Shearer, E Ann Black-Ziegelbein, Michael S Hildebrand, Robert W Eppsteiner, Harini Ravi, Swati Joshi, Angelica C Guiffre, Christina M Sloan, Scott Happe, Susanna D Howard, Barbara Novak, Adam P DeLuca, Kyle R Taylor, Todd E Scheetz, Terry A Braun, Thomas L Casavant, William J Kimberling, Emily M LeProust, Richard JH Smith
GRIN2A mutations cause epilepsy-aphasia spectrum disorders
Gemma L Carvill, Brigid M Regan, Simone C Yendle, Brian J O'Roak, Natalia Lozovaya, Nadine Bruneau, Nail Burnashev, Adiba Khan, Joseph Cook, Eileen Geraghty, Lynette G Sadleir, Samantha J Turner, Meng-Han Tsai, Richard Webster, Robert Ouvrier, John A Damiano, Samuel F Berkovic, Jay Shendure, Michael S Hildebrand, Pierre Szepetowski